Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease

Total Page:16

File Type:pdf, Size:1020Kb

Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease J Am Soc Nephrol 9: 1924-1930. 1998 Effect of Single Dose Resin-Cathartic Therapy on Serum Potassium Concentration in Patients with End-Stage Renal Disease CHRISTINE GRUY-KAPRAL, MICHAEL EMMETT, CAROL A. SANTA ANA, JACK L. PORTER, JOHN S. FORDTRAN, and KENNETH D. FINE Departnzent of Internal Medicine, Baylor Universirs’ Medical Center, Dallas, Texas. Abstract. Hyperkalemia in patients with renal failure is fre- slightly (0.4 mEqIL) during the I 2-h experiment. This rise was quently treated with a cation exchange resin (sodium polysty- apparently abrogated by some of the regimens that included rene sulfonate, hereafter referred to as resin) in combination resin; this may have been due in part to extracellular volume with a cathartic, but the effect of such therapy on serum expansion caused by absorption of sodium released from resin. potassium concentration has not been established. This study Phenolphthalein regimens were associated with a slight rise in evaluates the effect of four single-dose resin-cathartic regimens serum potassium concentrations (similar to placebo); this may and placebo on 5 different test days in six patients with chronic have been due to extracellular volume contraction produced by renal failure. Dietary intake was controlled. Fecal potassium high volume and sodium-rich diarrhea and acidosis secondary output and serum potassium concentration were measured for to bicarbonate losses. None of the regimens reduced serum 12 h. Phenobphthalein alone caused an average fecal potassium potassium concentrations, compared with baseline levels. Be- output of 54 mEq. The addition of resin caused an increase in cause single-dose resin-cathartic therapy produces no or only insoluble potassium output but a decrease in soluble potassium trivial reductions in serum potassium concentration, and be- output; therefore, there was no significant effect of resin on cause this therapy is unpleasant and occasionally is associated total potassium output. Sorbitol plus resin caused less potas- with serious complications, this study questions the wisdom of sium output than phenolphthalein plus resin. On placebo ther- its use in the management of acute hyperkabernic episodes. apy, the average serum potassium concentration increased The usual regimen used to treat acute hyperkalernia in patients serum potassium concentration fell over a period of several with renal failure includes administration of a cation exchange days, the study did not discriminate between the effects of resin (sodium polystyrene sulfonate, Kayexalate#{174}, hereafter resin-sorbitol, hypertonic glucose, or the extremely low potas- referred to as resin), together with a cathartic, usually sorbitol sium diet. In the era of chronic hemodialysis, it has become (1-6). The cathartic is believed to facilitate resin binding of common practice to administer single doses of resin-cathartic potassium by ensuring that the resin has adequate contact with in the management of acute hyperkalemia. However, as before, potassium-containing gastrointestinal secretions. Independent the efficacy of resin-cathartic therapy for acute hyperkabemia of any facilitory effect on resin binding of potassium, the has not been clarified due to the simultaneous use of other cathartic also causes loss of soluble potassium in diarrheal fluid potassium-lowering treatments, including glucose and insulin (I ,2,7). Presumably, therefore, the resin and the cathartic act in infusions, sodium bicarbonate, and/or f32-agonists. a synergistic manner to remove potassium from the body. In a previous experiment in healthy subjects (9), we found Moreover, the cathartic may prevent resin-induced constipa- that gastrointestinal excretion of potassium was greater after tion or fecab impaction ( 1,8). phenobphthalein-docusate (hereafter referred to as phenol- The early study (1 ) that introduced resin-cathartic therapy phthalein) than after sorbitol, and that addition of resin to either was carried out before the advent of chronic hemodiabysis. laxative caused only modest additional fecal potassium excre- Hyperkalemic patients were treated for several days with re- tion. The subjects used in that experiment had normal renal peated doses of resin-sorbitol and with a diet consisting of 50% function, and they were given potassium intravenously to pre- dextrose in water or Karo syrup and ginger ale. Although vent a net loss of potassiurn frorn the body. Therefore, this earlier study did not address whether resin-cathartic regimens could reduce the serum potassium concentration. Because a benefit of resin-cathartic therapy has not been Received October 20, 1998. Accepted March 9, 1998. clearly established, and because this therapy is unpleasant, Correspndence to Dr. Kenneth D. Fine, Baylor University Medical Center, poorly tolerated, and occasionally results in significant or even 2nd Floor HOB. 3500 Gaston Avenue Dallas, TX 75246. fatal complications 1,6,8, 10- 16), we performed a controlled l()46-6673/090l0- I924503.00/0 ( Journal of the American Society of Nephrology study on the effect of several single-dose resin-cathartic regi- Copyright 0 1998 by the American Society of Nephrology rnens in patients with end-stage renal disease. We analyzed the J Am Soc Nephrol 9: 1924-1930. 1998 Resin-Cathartics and Serum K Concentration 1925 effect of these regimens on serum potassium concentration and Table 1. Treatment regimens on the amount of potassium that is removed from the body. Placebo: 8 gelatin capsules with 500 ml of water Sodium polystyrene sulfonate: 30 g of resin with 500 ml of Materials and Methods water Patients Phenolphthalein-docusate: 8 tablets” with 500 ml of water Six patients with chronic renal failure maintained on hemodialysis Phenolphthabein-docusate plus resin: 8 tablets,” 30 g of resin volunteered for the study. This research was approved by the Institu- with 500 ml of water tional Review Board for Human Protection of Baylor University Sorbitol plus resin: 60 g of sorbitob, 30 g of resin with 500 Medical Center. and informed consent was obtained. ml of water a Given as Correctol#{174}; each tablet contains 65 mg of yellow Protocol phenolphthalein and 100 mg of docusate sodium. The patients underwent five studies on five separate experimental days, with at least I wk between each study. Patients were studied 2 d after a dialysis treatment and I d before their next dialysis session. In Results random order, they were treated with one of the five regimens listed 12-Hour Fecal Output of Potassium after Cathartic in Table I . Four hours after treatment, the patients ingested a standard Regimens meal containing 15.2 ± 2.2 mEq of sodium and 21.4 ± 1.4 mEq of Average results are shown in Table 2. Total fecal potassium potassium. No other foods or beverages (including water) were con- output after phenolphthalein alone was 54 mEq; of this sumed during the study. Intravenous fluid was not administered. amount, 46 mEq (85%) was dissolved in stool water, and the Serum potassium concentration was measured just before, and at 4, 8, and 12 h after treatment; a free-flowing peripheral vein was used remainder was insoluble. When 30 g of resin was ingested rather than the vascular access to avoid risk of access damage. Stools together with phenolphthalein, I 7 g of resin (57% of the were collected for I 2 h after each treatment to quantify fecal potas- ingested dose) was excreted; this was associated with an I 1 sium, sodium, and resin output. The patients did not excrete any urine mEq average rise in the output of insoluble potassium (P < during the experimental periods. 0.05). However, addition of resin was also associated with a 21 rnEqfL reduction in soluble potassium concentration and with a 17 mEq fall in soluble potassium output (P values not Analytical Methods and Calculations significant). The resin-induced rise in insoluble potassium out- Water and solid content of stool were measured by weighing before put was offset by the fall in soluble potassium output, and resin and after lyophilization. Sodium and potassium concentrations were therapy therefore did not increase total potassium excretion. measured by flame photometry. Calcium and magnesium concentra- The ingestion of sorbitol and 30 g of resin resulted in the tions were measured by atomic absorption spectroscopy. Soluble stool cation outputs were calculated as the product of the stool supernatant fecal excretion of only 9.3 g of resin (3 1 % of the ingested cation concentration and the grams of total fecal water (determined by dose). Fecal excretion of total potassium was less with sorbitol lyophilization of stool). Total stool output of cations was calculated as plus resin than with phenolphthalein plus resin, in agreement the product of stool weight and cation concentration of an acid- with an earlier study in healthy subjects (9). digested stool sample. Insoluble cation output is the difference be- tween total and soluble cation output. Plasma concentrations of chlo- 12-Hour Fecal Output of Sodium after Cathartic ride, bicarbonate, and glucose were measured by automated analysis. Regimens Stool resin concentration was estimated by measuring stool cation As shown in Table 2, when patients ingested phenobphtha- binding capacity. First, all cation binding sites in an aliquot of stool were lein alone, fecab sodium output existed almost exclusively in converted to the lithium form by suspending the stool in a concentrated the soluble state. When 30 g of resin was ingested with phe- solution (I mol/L) of lithium chloride. Unbound lithium was removed by nobphthalein, fecal output contained 1 7 g of resin, and there repeated washing and centrifugation. The precipitate was then suspended in water, and concentrated potassium chloride was added to displace the was a marked increase in fecal excretion of both soluble and bound lithium. The amount of lithium released into water, measured by insoluble sodium. After sorbitol plus resin, the fecal output atomic absorption spectroscopy, is equal to the mEq of cation binding contained less resin and less sodium than when phenolphtha- sites of stool. The resin content of a 12-h stool collection in mEq is the 1cm plus resin was ingested.
Recommended publications
  • 3.2.2 Misuse of Stimulant Laxatives
    Medicines Adverse Reactions Committee Meeting date 10/06/2021 Agenda item 3.2.2 Title Misuse of stimulant laxatives Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Bisacodyl Bisacodyl Laxative (Pharmacy Health) PSM Healthcare Limited trading as API tablet Consumer Brands Dulcolax tablet Sanofi-Aventis New Zealand Limited Dulcolax Suppository Sanofi-Aventis New Zealand Limited *Lax-Suppositories Bisacodyl AFT Pharmaceuticals Limited *Lax-Tab tablet AFT Pharmaceuticals Limited Docusate sodium *Coloxyl tablet Pharmacy Retailing (New Zealand) Limited trading as Healthcare Logistics Docusate sodium + Coloxyl with Senna tablet Pharmacy Retailing (New Zealand) sennosides Limited trading as Healthcare Logistics *Laxsol tablet Pharmacy Retailing (New Zealand) Limited trading as Healthcare Logistics Glycerol *Glycerol Suppositories PSM Healthcare Limited trading as API Consumer Brands Sennosides *Senokot tablet Reckitt Benckiser (New Zealand) Limited Sodium picosulfate Dulcolax SP Drops oral solution Sanofi-Aventis New Zealand Limited PHARMAC funding *Pharmaceutical Schedule Lax-Tab tablets, Lax-Suppositories Bisacodyl, Coloxyl tablets and Glycerol Suppositories are fully-funded only on a prescription. Senokot tablets are part- funded. Previous MARC Misuse of stimulant laxatives has not been discussed previously. meetings International action Following a national safety review published in August 2020, the MHRA in the UK has introduced pack size restrictions, revised recommended ages for use
    [Show full text]
  • Assessment Report on Ricinus Communis L., Oleum Final
    2 February 2016 EMA/HMPC/572973/2014 Committee on Herbal Medicinal Products (HMPC) Assessment report on Ricinus communis L., oleum Final Based on Article 10a of Directive 2001/83/EC as amended (well-established use) Herbal substance(s) (binomial scientific name Ricinus communis L., oleum (castor oil) of the plant, including plant part) Herbal preparation Fatty oil obtained from seeds of Ricinus communis L. by cold expression Pharmaceutical forms Herbal preparation in liquid or solid dosage forms for oral use Rapporteur C. Purdel Peer-reviewer B. Kroes 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Search and assessment methodology ..................................................................... 6 2. Data on medicinal use ........................................................................................................ 6 2.1. Information about products on the market .............................................................
    [Show full text]
  • Chronic Constipation: an Evidence-Based Review
    J Am Board Fam Med: first published as 10.3122/jabfm.2011.04.100272 on 7 July 2011. Downloaded from CLINICAL REVIEW Chronic Constipation: An Evidence-Based Review Lawrence Leung, MBBChir, FRACGP, FRCGP, Taylor Riutta, MD, Jyoti Kotecha, MPA, MRSC, and Walter Rosser MD, MRCGP, FCFP Background: Chronic constipation is a common condition seen in family practice among the elderly and women. There is no consensus regarding its exact definition, and it may be interpreted differently by physicians and patients. Physicians prescribe various treatments, and patients often adopt different over-the-counter remedies. Chronic constipation is either caused by slow colonic transit or pelvic floor dysfunction, and treatment differs accordingly. Methods: To update our knowledge of chronic constipation and its etiology and best-evidence treat- ment, information was synthesized from articles published in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Levels of evidence and recommendations were made according to the Strength of Recommendation taxonomy. Results: The standard advice of increasing dietary fibers, fluids, and exercise for relieving chronic constipation will only benefit patients with true deficiency. Biofeedback works best for constipation caused by pelvic floor dysfunction. Pharmacological agents increase bulk or water content in the bowel lumen or aim to stimulate bowel movements. Novel classes of compounds have emerged for treating chronic constipation, with promising clinical trial data. Finally, the link between senna abuse and colon cancer remains unsupported. Conclusions: Chronic constipation should be managed according to its etiology and guided by the best evidence-based treatment.(J Am Board Fam Med 2011;24:436–451.) copyright. Keywords: Chronic Constipation, Clinical Review, Evidence-Based Medicine, Family Medicine, Gastrointestinal Problems, Systematic Review The word “constipation” has varied meanings for was established in 1991 by Drossman et al, primar- different individuals.
    [Show full text]
  • Comparison of Two Cathartic Preparations, Peg-Electrolytes Solution and Sodium Phosphate Salts, As Means for Large Bowel Preparation for Colonoscopy
    276 ANNALS OF GASTROENTEROLOGY 2004,C. FOTIADIS, 17(3):276-279 et al Original article Comparison of two cathartic preparations, peg-electrolytes solution and sodium phosphate salts, as means for large bowel preparation for colonoscopy N. Antonakopoulos, I. Kyrlagkitsis, V. Xourgias, D.G. Karamanolis SUMMARY period of preparation, less inconvenience for the patient and better bowel cleansing. Twenty years ago, the whole The ideal bowel preparation for colonoscopy must combine procedure required a three-day low-residue diet, a the characteristics of effectiveness with the least side effects. laxative (bisacodyl) two days before the examination, a We compared the relatively novel cathartic preparation of cathartic preparation the previous day and an enema on R sodium phosphate salts (Fleet Phospho-soda ) with the the day of the examination.1 Today a single-day prepa- R widely used PEG-electrolytes solution (Klean-prep ). Fifty- ration with an oral cathartic solution is adequate. two consecutive patients referred for colonoscopy were randomised to receive either sodium phospate salts or PEG The aim of the present study was to compare the novel electrolytes. The evaluation of the two preparations was cathartic preparation of sodium phosphate salts (Fleet R based on two separate questionnaires, one completed by the Phospho-soda ), to the widely used PEG-electrolytes R endoscopist who ignored the kind of bowel preparation used solution (Klean-prep ), in terms of efficacy and tolerance and the other by the patient. Bowel preparation with sodium by the patient. phospate salts was more effective in bowel cleansing and better tolerated than PEG-electrolytes solution in terms of MATERIALS AND METHODS difficulty in intake and swallowing, fatigue, the presence of colicky abdominal pain, flatulence, vomiting and perianal We included all outpatients who underwent colono- irritation (p<0,05).
    [Show full text]
  • DEXEDRINE® (Dextroamphetamine Sulfate) SPANSULE® Sustained-Release Capsules and Tablets
    DX:L58 PRESCRIBING INFORMATION DEXEDRINE® (dextroamphetamine sulfate) SPANSULE® sustained-release capsules and Tablets WARNING AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS. DESCRIPTION DEXEDRINE (dextroamphetamine sulfate) is the dextro isomer of the compound d,l-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine, and is present in all forms of DEXEDRINE as the neutral sulfate. Structural formula: SPANSULE capsules: Each SPANSULE sustained-release capsule is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period. Each capsule, with brown cap and clear body, contains dextroamphetamine sulfate. The 5-mg capsule is imprinted 5 mg and 3512 on the brown cap and is imprinted 5 mg and SB on the clear body. The 10-mg capsule is imprinted 10 mg—3513—on the brown cap and is imprinted 10 mg—SB—on the clear body. The 15-mg capsule is imprinted 15 mg and 3514 on the brown cap and is imprinted 15 mg and SB on the clear body. A narrow bar appears above and below 15 mg and 3514. Product reformulation in 1996 has caused a minor change in the color of the time-released pellets within each capsule.
    [Show full text]
  • Getting the Most from the Universal Antidote
    Getting the Most from the Universal Antidote Activated charcoal has been called the most as antibiotics, vitamins or amino acids. Antibiotic important “universal antidote” in the treatment of therapy should be administered parenterally intoxification by chemical agents. The term when activated charcoal is used. Fluids to antidote may be misleading since activated correct acid/base, hydration and electrolyte charcoal does not directly counteract the effects imbalances should be administered. of a poison and may not be effective with some toxicants such as heavy metals. However, finely Emesis ground activated charcoal is useful in the treatment of many poisons in animals and If an oral emetic such as syrup of ipecac, humans. hydrogen peroxide or apomorphine hydrochloride is used, activated charcoal should Activated charcoal is an amophorous form of not be administered until after emesis (vomiting). carbon in that it has no regular atomic structure Emesis is most productive if performed within 2- and differs from common charcoal that contains 3 hours post ingestion. Feeding the animal a other organic residues. Charcoal is obtained by small moist meal before inducing vomiting can burning carbon-containing materials. Charcoal increase the chances of an adequate emesis. becomes activated by heating it to extremely Emetics generally empty 40-60% of the stomach high temperatures in the absence of oxygen contents. thereby removing the residual non-carbon elements and producing a porous internal Emesis is contraindicated with ingestion of microstructure having an extremely high surface alkalis, acids, corrosive agents or hydrocarbons area. A single gram of activated charcoal USP due to the risk of chemical burns or aspiration.
    [Show full text]
  • Saline Cathartics
    Saline Cathartics Saline cathartics or purgatives are agents that quicken and increase evacuation from the bowl. Laxatives are mild cathartics. Cathartics are used: to ease defecation in patients with painful hemorrhoids or other rectal disorders and to avoid excessive straining and concurrent increase in abdominal pressure in patients with hernias Or to avoid potentially hazardous rise in B.P. during defecation in patients with hypertension, cerebral coronary or other arterial disease Or to relieve acute constipation Or to remove solid material from intestinal tract prior to certain roentgenographic studies. Laxative should only be used for short term therapy as prolonged use may lead to loss of spontaneous bowl rhythm upon which normal evacuation depends, causing patient to become dependent on laxatives, the so called laxative effect. Constipation is the infrequent or difficult evacuation of the feces. It may be due to a person resisting the natural urge to defecate, causing the fecal material which remains in the colon to lose fluid and to become relatively dry and hard. Constipation can also be due to intestinal atony, intestinal spasm, emotions, drugs and diet. Many a time constipation can be helped by eating food such as natural laxatives or food with large roughages. Four types of laxatives are known: 1. Stimulants 2. Bulk forming 3. Emollient 4. Saline cathartics Stimulants act by local irritation on the intestinal tract which increase peristaltic activity. They include phenolphthalein, aloin, cascara extract, rhubarb extract, senna extract, podophyllin, castor oil, bisacodyl, calomel etc. Bulk forming laxatives are made from cellulose, sodium carboxyl methyl cellulose and karaya gum.
    [Show full text]
  • A Consensus Document on Bowel Preparation Before Colonoscopy
    Consensus Statement A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force From The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal Endoscopy (ASGE), and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Steven D. Wexner, M.D., Task Force Chair,1 David E. Beck, M.D.2 (ASCRS), Todd H. Baron, M.D.3 (ASGE), Robert D. Fanelli, M.D.4 (SAGES), Neil Hyman, M.D.5 (ASCRS), Bo Shen, M.D.6 (ASGE), Kevin E. Wasco, M.D.7 (SAGES) 1 Department of Colorectal Surgery, Cleveland Clinic Florida, Weston, Florida 2 Department of Colon and Rectal Surgery, Ochsner Clinic Foundation, New Orleans, Louisiana 3 Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 4 Surgical Specialists of Western New England, PC/Department of Surgery, Berkshire Medical Center, Pittsfield, Massachusetts 5 Department of Surgery, University of Vermont College of Medicine, Burlington, Vermont 6 Department of Gastroenterology/Hepatology, Cleveland Clinic Foundation, Cleveland, Ohio 7 Surgical Associates of Neenah, S.C., Neenah, Wisconsin This document appears simultaneously in the June 2006 issues of Diseases of the Colon & Rectum, Surgical Endoscopy, and Gastro- intestinal Endoscopy. This document was reviewed and approved by the SAGES Board of Governors, the ASCRS Standards Committee and Executive Council, and the ASGE Governing Board. Addendum provides manufacturers’ information for all products discussed in this document. Correspondence to: Steven D. Wexner, M.D., Department of Colorectal Surgery, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, Florida 33331, e-mail: [email protected] Dis Colon Rectum 2006; 49: 792–809 DOI: 10.1007/s10350-006-0536-z * The American Society of Colon and Rectal Surgeons Published online: 02 May 2006 792 Vol.
    [Show full text]
  • LARISSA LUCENA PÉRICO AVALIAÇÃO DOS MECANISMOS DE AÇÃO ENVOLVIDOS NA ATIVIDADE ANTIULCEROGÊNICA DE Serjania Marginata Casa
    UNIVERSIDADE ESTADUAL PAULISTA “Júlio de Mesquita Filho” INSTITUTO DE BIOCIÊNCIAS DE BOTUCATU LARISSA LUCENA PÉRICO AVALIAÇÃO DOS MECANISMOS DE AÇÃO ENVOLVIDOS NA ATIVIDADE ANTIULCEROGÊNICA DE Serjania marginata Casar. FRENTE À DOENÇA ULCEROSA PÉPTICA EXPERIMENTAL Botucatu – SP 2014 UNIVERSIDADE ESTADUAL PAULISTA “Júlio de Mesquita Filho” INSTITUTO DE BIOCIÊNCIAS DE BOTUCATU LARISSA LUCENA PÉRICO AVALIAÇÃO DOS MECANISMOS DE AÇÃO ENVOLVIDOS NA ATIVIDADE ANTIULCEROGÊNICA DE Serjania marginata FRENTE À DOENÇA ULCEROSA PÉPTICA EXPERIMENTAL ORIENTADORA: PROF. ADJA. CLÉLIA AKIKO HIRUMA LIMA COORIENTADORA: PROFA. DRA. LÚCIA REGINA MACHADO DA ROCHA Dissertação apresentada ao Departamento de Farmacologia do Instituto de Biociências de Botucatu UNESP, como requisito para a obtenção do título de Mestre em Ciências Biológicas (área de concentração: Farmacologia). Botucatu – SP 2014 BANCA EXAMINADORA __________________________________________ 1º. Titular/ Presidente Profa Adja. Clélia Akiko Hiruma-Lima (UNESP/Botucatu) __________________________________________ 2º. Titular Profa Dra Alessandra Gambero (Universidade São Francisco/Bragança Paulista) __________________________________________ 3º. Titular Profa Dra Patricia Fidelis de Oliveira Gregolini (UNESP/Botucatu) Auxílio Financeiro: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) BIOTA- FAPESP/SP AGRADECIMENTOS Agradeço primeiramente a Deus por permitir que tudo pudesse ser realizado. Agradeço à minha família que sempre me apoiou nos momentos difíceis e compartilhou minhas alegrias. Aos meus pais, Luzia e Vanderlei, que são exemplos de ética e profissionalismo e que sempre me incentivaram nesta busca ao conhecimento e ao crescimento profissional, sempre com muito amor e carinho. Ao meu irmão, Rafael, pelo apoio, amor, carinho e compreensão. Agradeço a Deus pela família que tenho. A Tainara B. Ferrari que sempre esteve comigo me apoiando e me aconselhando. Ela me abraçou nos dias de choro e também sorriu comigo nos momentos de alegria.
    [Show full text]
  • DEXEDRINE® (Dextroamphetamine Sulfate) SPANSULE® Sustained Release Capsules CII Rx Only
    DEXEDRINE® (dextroamphetamine sulfate) SPANSULE® sustained release capsules CII Rx Only WARNING: AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS. DESCRIPTION: DEXEDRINE (dextroamphetamine sulfate) is the dextro isomer of the compound d,l-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine, and is present in all forms of DEXEDRINE as the neutral sulfate. Structural formula: SPANSULE capsules: Each SPANSULE sustained-release capsule is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period. Each capsule, with brown cap and natural body, contains dextroamphetamine sulfate. The 5-mg capsule is imprinted in white with IX and 5 mg on the brown cap and is imprinted in white with 673 and 5 mg on the natural body. The 10-mg capsule is imprinted in white with IX and 10 mg on the brown cap and is imprinted in white with 674 and 10 mg on the natural body. The 15-mg capsule is imprinted in white with IX and 15 mg on the brown cap and is imprinted in white with 675 and 15 mg on the natural body. Product reformulation in 1996 has caused a minor change in the color of the time-released pellets within each capsule.
    [Show full text]
  • Mineral Oil, General Entry
    ENVIRONMENTAL CONTAMINANTS ENCYCLOPEDIA MINERAL OIL, GENERAL ENTRY July 1, 1997 COMPILERS/EDITORS: ROY J. IRWIN, NATIONAL PARK SERVICE WITH ASSISTANCE FROM COLORADO STATE UNIVERSITY STUDENT ASSISTANT CONTAMINANTS SPECIALISTS: MARK VAN MOUWERIK LYNETTE STEVENS MARION DUBLER SEESE WENDY BASHAM NATIONAL PARK SERVICE WATER RESOURCES DIVISIONS, WATER OPERATIONS BRANCH 1201 Oakridge Drive, Suite 250 FORT COLLINS, COLORADO 80525 WARNING/DISCLAIMERS: Where specific products, books, or laboratories are mentioned, no official U.S. government endorsement is intended or implied. Digital format users: No software was independently developed for this project. Technical questions related to software should be directed to the manufacturer of whatever software is being used to read the files. Adobe Acrobat PDF files are supplied to allow use of this product with a wide variety of software, hardware, and operating systems (DOS, Windows, MAC, and UNIX). This document was put together by human beings, mostly by compiling or summarizing what other human beings have written. Therefore, it most likely contains some mistakes and/or potential misinterpretations and should be used primarily as a way to search quickly for basic information and information sources. It should not be viewed as an exhaustive, "last-word" source for critical applications (such as those requiring legally defensible information). For critical applications (such as litigation applications), it is best to use this document to find sources, and then to obtain the original documents and/or talk to the authors before depending too heavily on a particular piece of information. Like a library or many large databases (such as EPA's national STORET water quality database), this document contains information of variable quality from very diverse sources.
    [Show full text]
  • Constipation (Women)
    Comments on the ACD Received from the Public Through the NICE Website Name Graham Wallis Role NHS Professional Other role Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 Following discussions within the PCT, NHS Trafford's (Appraisal Committee's comments are as follows: preliminary recommendations) The prevalence estimation is taken at the lower end of the scale (8% to 52%) and in the PCT's view is unrealistic. There are many patients with refractory constipation who put up with their symptoms as there is no treatment that works for them at present. There is likely to be media publicity which will be targeted at this group and result in a significant representation of the clinical problem. Whilst we think it is unlikely that this would be at the upper end of that spectrum a figure of circa 15% is very likely. If the treatment pathway is that this treatment will be considered after assessment by a specialist then there will be an increase in referral and OPD attendance as a consequence with an additional cost implication. The PCT disagrees with the conclusion and feel that more evidence of long term safety and identification of the characteristics of those likely to respond is required. There is a lack of trial data comparing this directly to other treatments. The PCT's view is that this should only be approved in the context of a clinical trial designed to answer these questions. Section 2 (clinical need and practice) Section 3 (The technologies) Section 4 The PCT already spends '£340,000 on laxative preparations (Evidence and (0.09% of the budget) and as the group we are considering do interpretation) not respond there is unlikely to be a concomitant reduction in the prescribing of these drugs.
    [Show full text]